Previous Statements by MDVN
» Medivation CEO Discusses Q3 2010 Results - Earnings Call Transcript
» Medivation, Inc. Q2 2010 Earnings Call Transcript
» Medivation, Inc. Q1 2010 Earnings Call Transcript
A cancer research meeting beginning on Friday will provide investors with an opportunity to inspect updated clinical data on two competing PARP inhibitors from Clovis Oncology and Tesaro.
The company has spent $600 million weighing a potential breakup.